drugset / Trial / NCT02938442
Vaccination of Triple Negative Breast Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III triple negative breast cancer (TNBC). This study will compare the vaccine plus standard neoadjuvant chemotherapy and surgery to standard neoadjuvant chemotherapy and surgery alone.
Timeline
- Start
- 2019-01-25
- Primary completion
- 2023-01-09
- Completion
- 2023-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | P10s-PADRE | Peptide | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | — |